Accelerate to discover

Back to filter

Related topics

IncuCyte webinar: high throughput approach to developing T- Cell immunotherapies

Sartorius

Jun 17, 2019

Immunotherapy for cancers involves artificially prompting the immune system to treat cancer. Many cancer cells have...

Low-dose imaging in a new preclinical total-body PET/CT scanner

Bruker Biospin

Jun 12, 2019

Ionizing radiation constitutes a health risk to imaging scientists and study animals. Both PET and CT produce ionizing...

Fluxion Biosciences and National Cancer Institute cooperate to validate IsoFlux for sequencing

Fluxion Biosciences

Jun 12, 2019

Fluxion with IsoFlux has partnered with the Cleveland Clinic. They are aiming to improve sensitivity by timing the...

New insight into Cas9 off-target activity

LUMICKS

Jun 7, 2019

Scientists at the MRC London Institute of Medical Sciences and AstraZeneca studied how CRISPR-Cas9 differentiates...

Jun 18, 2019

Join the AVANCE Track & Keep your MRI on Track

Bruker Biospin

Jun 4, 2019

Your research depends on the scientific advances that you make with your MRI instrument. Take your instrument and your...

A novel method for isolating high-quality UHMW DNA from animal and human tissues

BioNano Genomics

May 31, 2019

New isolation protocol for isolating high-quality UHMW DNA from 10 mg of freshly frozen or liquid-preserved animal and...

ParaVision 7 software

Bruker Biospin

May 27, 2019

The preclinical MRI software ParaVision 7 delivers unsurpassed image quality and enhanced productivity for both routine...

Jun 18, 2019

HLS-CATCH: Cas-9 assisted gene purification

Sage Science

May 24, 2019

The CATCH process  provides researchers with the most direct access to genes for study. Target regions are defined with...

Show all topics (10)

Quantifying the impact of a CD19-BiTE combining flow cytometry & real-time cell analysis

Jun 9, 2017

The ability to quantitatively correlate T cell biomarker expression/secretion with  target cell killing is critical in both basic and applied studies of tumor immunology. Coupling flow cytometry with multiplex bead-based immunoassays enables quantitative measurement of multiple secreted targets in a single sample simultaneously. In this Application Note, we demonstrate a workflow involving the use of an xCELLigence Real-Time Cell Analysis (RTCA) instrument in conjunction with a NovoCyte flow cytometer to study both CTL-mediated destruction of tumor cells and the corresponding secretion of cytokines and cytolytic proteins by CTLs. Representing a promising new class of therapeutics, bispecific T-cell engagers (BiTEs) harness the power of the adaptive immune response by enhancing the ability of CTLs to specifically recognize and eliminate tumors. For example, CD19-BiTEs  are designed to simultaneously bind CD3 on CTLs and CD19 on cells of B cell lineage, thereby enhancing the efficiency of CTL effector functions against various B cell derived tumors. Herein, the enhancement effects of CD19-BiTEs have been evaluated using three distinct assays. While target cell death was monitored using an RTCA impedance assay and a flow cytometry-based cytolysis assay, secretion of cytokines and cytolytic proteins was quantified in a bead-based multiplex flow cytometry assay.

Read more

Scientific paper
Application
Product news

Related technologies: Conventional flow cytometry

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey